Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-197-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
At some point in their lives, nearly one-third of patients who have previously suffered from a varicella infection or have been immunized for varicella (over 99% of Americans) will be afflicted by shingles. Despite the availability of highly efficacious vaccine products designed to prevent this pathology, less than one-fourth of susceptible adults have been properly immunized. Pharmacists qualified to administer immunizations are in a unique position to increase the frequency of all vaccinations, to include those capable of preventing the occurrence of shingles.
This CE activity will provide pharmacists with education on several topics surrounding shingles vaccination, with particular emphasis on risk factors, disease burden, ACIP recommendations, and approaches pharmacists can take to increase the uptake of immunization. Interactive questions will serve to demonstrate and reinforce how to overcome common challenges and barriers to achieving immunization best practices.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Describe the disease burden, risk factors, and treatment of shingles.
- Outline the current ACIP recommendations for shingles vaccination, including the economic considerations of treatment.
- Differentiate shingles vaccines based on mechanism of action, efficacy, adverse events, patient selection, and dosing.
- List pharmacist activities and communication strategies to increase shingles vaccination rates.
Kaitlyn R. Rivard, PharmD, BCPS, BCIDP, AAHIVP
Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacist
Kenneth Schmader, MD
Professor of Medicine
Duke University Medical Center
Release Date: August 15, 2019
Expiration Date: August 15, 2020
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-197-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Rivard has no relevant commercial or financial relationships to disclose. Dr. Schmader has received research grant support from GlaxoSmithKline.
This activity is provided by ProCE, Inc. and is supported by an educational grant from GlaxoSmithKline.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.